DLP (Dexlansoprazole) delayed release capsule has been characterized as a
gastric Proton Pump Inhibitor (PPI) that blocks the final step of gastric acid
production. It is the R-enantiomer of Lansoprazole (a racemic mixture of the R
and S-enantiomers). DLP (Dexlansoprazole) capsule contains enteric coated
pellets with different pH - dependent dissolution profiles. The formulation of DLP
(Dexlansoprazole) utilizes Dual Delayed Release (DDR) technology which
results in plasma concentration-time profile with two distinct peaks; the first
peak occurs within 1 to 2 hours after administration, followed by a second peak
within 4 to 5 hours. No accumulation of Dexlansoprazole occurs after multiple
once daily doses of DLP.